About

PDC Therapeutics is a nanomedicines biotech company, developing targeted Polymer Drug Conjugates which provide cancer patients with an optimal therapeutic index. We are exploiting the proprietary and clinically validated platform technology of parent company RS Research, a clinical stage academic spin-off which has discovered a pioneering class of nanocarriers with a versatile targeting capability. Our nanomedicine pipeline currently houses proprietary programs in various stages of preclinical and clinical development. We manufacture our products at our own GMP certificated production facility for clinical batch lyophilized oncology drugs. We look forward to leveraging our Sagitta™ nanocarrier platforms to enrich partners' pipelines by developing cutting-edge targeted therapies. About PDC Therapeutics PDC Therapeutics is a biotechnology start-up developing targeted Polymer-Drug Conjugate technologies that aim to provide patients with an optimal therapeutic index. PDC Therapeutics’ proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability. Cooperating with multinational pharmaceutical companies through co-development programs, PDC Therapeutics is supported by an industry-experienced board of scientific and supervisory experts around the world. The most advanced candidate utilizing a Sagitta® platform is developed by RS Research, which has a nanomedicine pipeline in various stages of preclinical and clinical development. RS Research also has a GMP-certified production facility for clinical batch drug candidates. We look forward to leveraging our Sagitta® nanocarrier platforms to enrich partners' pipelines by developing cutting-edge targeted therapies. About PDC Therapeutics PDC Therapeutics is a biotechnology start-up developing targeted Polymer-Drug Conjugate technologies that aim to provide patients with an optimal therapeutic index. PDC Therapeutics’ proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability. Cooperating with multinational pharmaceutical companies through co-development programs, PDC Therapeutics is supported by an industry-experienced board of scientific and supervisory experts around the world. The most advanced candidate utilizing a Sagitta® platform is developed by RS Research, which has a nanomedicine pipeline in various stages of preclinical and clinical development. RS Research also has a GMP-certified production facility for clinical batch drug candidates. We look forward to leveraging our Sagitta® nanocarrier platforms to enrich partners' pipelines by developing cutting-edge targeted therapies. Unlocking the Potential of Targeted Therapies with No Compromise, with Clinically Validated Drug Delivery Technologies: PDC Therapeutics is a biotechnology start-up, founded by 2024 EIC European Prize for Women Innovators winner Prof. Rana Sanyal and Sena Nomak, developing targeted Polymer-Drug Conjugate technologies that aim to provide patients with an optimal therapeutic index. PDC Therapeutics’ proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability. Cooperating with multinational pharmaceutical companies through co-development programs, PDC Therapeutics is supported by an industry-experienced board of scientific and supervisory experts around the world. -The most advanced candidate utilizing a Sagitta® platform is developed by RS Research, which has a nanomedicine pipeline in various stages of preclinical and clinical development. RS Research also has a GMP-certified production facility for clinical batch drug candidates. We look forward to leveraging our Sagitta® nanocarrier platforms to enrich partners' pipelines by developing cutting-edge targeted therapies. -Technology Platform: Sagitta®: Clinically validated Sagitta® biodegradable conjugation platforms are discovered to reinforce ideal performances in terms of the therapeutic index, pharmacokinetics and manufacturability that are experimentally proven to be translatable across species. Our Sagitta® nanocarriers are compatible with a broad spectrum of technology platforms used in conjugated drugs, including a wide range of targeting ligands/mAbs and linkers. Fine-tuning the selection of cleavable linkers enables controlled release of the payloads, improving the tolerability profile. All Sagitta® platforms are available for licensing and co-development opportunities. -Sagitta® Bir is a version of the platform with a water-soluble and biocompatible polymer backbone that enables the covalent linkage of multiple payload molecules. The lead candidate in RS Research’s pipeline (open for out-licensing) based on Sagitta® Bir has progressed to the dose-expansion phase in the ongoing Phase I clinical trial in the oncology domain. -Sagitta® Dui is another version of the platform, which is synthesized as a block copolymer and forms a micelle structure upon contact with water. Importantly, it enables a dual payload capacity such that while one payload is covalently linked, another payload is encapsulated in the micelle, yielding an increased loading capacity of over 50% by weight and a synergistic effect. The most advanced molecule in RS Research’s pipeline based on Sagitta® Dui is currently in the preclinical phase. Compared to Antibody-Drug Conjugates (ADCs), Sagitta® platforms offer distinct advantages by enabling the attachment of a significantly larger number of drugs per molecule. Sagitta® Bir boasts a Drug-to-Antibody Ratio (DAR) exceeding 30, while ng to the end of dose-finding activities in the ongoing Phase I clinical trial in the oncology domain. Sagitta® Dui achieves a DAR surpassing 400. This expanded payload capacity not only broadens the therapeutic possibilities but also allows for the utilization of less toxic drugs that are typically unsuitable for ADCs. -Sagitta Radix is a targeted radiopharmaceutical delivery platform capable of binding radionuclides such as gallium (Ga), zirconium (Zr), actinium (Ac), or lutetium (Lu), enhancing its utility in both therapeutic and diagnostic applications. Sagitta Radix’s design allows for precise targeting of disease sites via monoclonal antibodies (mAbs) or peptides, aiding with the decision-making process for theranostic applications. This platform holds promise for developing next-generation theranostics, leveraging its unique ability to bind and deliver radionuclides to specific cellular targets. -Why Sagitta®? Advantages Over ADCs and Conventional Platforms: • Expanded Payload Capacity: Deliver significantly higher drug amounts per carrier molecule. • Modular Targeting: Compatible with a wide range of ligands, including mAbs and peptides. • Controlled Release: Cleavable linkers allow for customized drug release kinetics. • Biodegradable Polymers: Engineered for safety, scalability and regulatory compliance. • Clinically Validated: Ongoing human trials with lead candidates demonstrate platform translatability across species and therapeutic areas. -Lead Asset: RS-0139: RS-0139 is the lead candidate of RS Research, a clinical-stage biotechnology start-up harvesting the remarkable therapeutic index offered by Sagitta® technology. RS-0139 was developed benefiting the remarkable therapeutic index offered by Sagitta® technology. It has progressed to the dose-expansion phase in the ongoing Phase Ib clinical trial in the oncology domain. RS-0139 leverages PDC Therapeutics’ proprietary Sagitta® Bir nanoparticles platform. It delivers the cytotoxic payload, targeting integrin receptors. Preclinical studies have consistently confirmed the improved therapeutic index of the payload delivered with our technology. The efficacy of RS-0139 also shows significant improvement in various xenograft models in oncology. -For more: RS-0139 Preclinical & Clinical Data: https://pdcbio.com/2023/rs-0139-a-novel-tumor-targeted-delivery-of-docetaxel/ Phase Ia/Ib Study Summary: https://pdcbio.com/2022/phase-ia-ib-study-of-rs-0139/ -Partnering & Business Development: PDC Therapeutics is actively pursuing co-development, licensing and out-licensing partnerships with biotech and pharmaceutical companies seeking: • Solutions for rescuing shelved or challenging compounds • New modalities for targeted delivery in oncology and beyond • Expansion into radiotheranostics or dual payload strategies • Platform technologies with established IP and clinical proof-of-concept We are particularly open to partnerships for therapeutic areas requiring high precision delivery, reduced off-target toxicity, or where existing modalities like ADCs have failed to meet expectations. -IP & Regulatory Readiness: The Sagitta® platforms are protected by two patent families filed in 2018 worldwide. Our technologies are supported by a GMP-certified manufacturing facility operated by RS Research, ensuring scalability and clinical readiness for our partners’ development programs. -Let’s Collaborate: At PDC Therapeutics, we believe that advanced delivery systems like Sagitta® will define the future of precision medicine. Whether you’re seeking a delivery solution to revive a stalled asset or a co-development partner to power your pipeline, we’re ready to collaborate. Visit us at the BIO International Convention Contact: info@pdcbio.com Website: pdcbio.com LinkedIn: PDC Therapeutics: https://www.linkedin.com/company/pdc-bio Twitter: @PDCTherapeutics: https://x.com/PDCTherapeutics